Who makes QLS1128 C-Dose 1~3 and Ritonavir?

QLS1128 C-Dose 1~3 and Ritonavir is developed by Qilu Pharmaceutical Co., Ltd..

What development phase is QLS1128 C-Dose 1~3 and Ritonavir in?

QLS1128 C-Dose 1~3 and Ritonavir is in Phase 1.

Last reviewed 2026-04-19 · How we verify

QLS1128 C-Dose 1~3 and Ritonavir

Qilu Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	QLS1128 C-Dose 1~3 and Ritonavir
Sponsor	Qilu Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

QLS1128 C-Dose 1~3 and Ritonavir CI brief — competitive landscape report
QLS1128 C-Dose 1~3 and Ritonavir updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI